Clinical Trial Update: A Clinical Study of Iparomlimab and Tuvonralimab Combined With Bevacizumab and Alternating Triweekly CAPOX/mCAPIRI Regimen as First-line Treatment for Unresectable Advanced Colorectal Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating the combination of iparomlimab and tuvonralimab with bevacizumab and alternating CAPOX/mCAPIRI as first-line therapy for unr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• Capecitabine (capecitabine)
• Irinotecan (Irinotecan)
• OXALIPLATIN (Oxaliplatin)
• Tuvonralimab (tuvonralimab)
• iparomlimab

Snippet

Sponsor: Jiangsu Cancer Institute & Hospital | Conditions: Metastatic Colorectal Cancer (CRC) | Phase 2 | Status: NOT_YET_RECRUITING